Sandoz acquires consumer skin care brand AmLactin®
Dec 15, 2016
Princeton, New Jersey, December 15, 2016– Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc. Under terms of the agreement, Upsher-Smith, through existing channels, will continue to distribute AmLactin® hand and body lotion products to most US customers for 60 days until fully transitioned to Sandoz.
Sandoz US President Peter Goldschmidt said, “Adding consumer skin care products to our successful branded and generic pharmaceutical portfolio will enable Sandoz to help even more patients with their skin care needs while continuing to grow a multi-faceted dermatology business.”
Financial terms of the agreement have not been disclosed.
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.